Pooled safety analysis of six phase IIb/III studies of bimekizumab 160 mg every 4 weeks in 848 patients with axSpA and 1409 with PsA: adverse events 129.6 and 126.9 per 100 patient-years, oral candidiasis 3.5 and 3.8; no active tuberculosis and no new safety signals.
RCTn = 2,257 patients
Mease et al. Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies